MAPT and early-onset autosomal dominant Alzheimer disease: I fully agree with the authors that the future of drug development for Alzheimer’s disease must be based on a multifaceted approach that integrates immunotherapy with new strategies that address other aspects, not only targeting amyloid and tau protein, but also mitochondrial and synaptic dysfunction, neuroinflammation, the brain–gut axis, genetic risk factors, and sex-specific pharmacogenomics.